目的 探究胎盤多肽聯(lián)合TACE方案治療晚期原發(fā)性肝癌的臨床療效。方法 收集2011年2月—2013年12月遼寧省腫瘤醫(yī)院收治的原發(fā)性肝癌患者88例,隨機分為對照組和治療組,每組44例。對照組采用經(jīng)導管介入肝動脈灌注化療栓塞術(TACE)治療,治療組在對照組基礎上每個TACE療法周期的1～14 d加用胎盤多肽注射液,8 mL加入250 mL生理鹽水中緩慢靜脈滴注,1次/d。兩組患者均連續(xù)治療4個周期。觀察兩組的臨床療效,同時比較兩組治療前后Karnofsky評分、免疫功能指標的變化以及藥物的毒副反應發(fā)生情況。結果 治療后,對照組和治療組的總有效率分別為13.64%、31.82%,兩組比較差異有統(tǒng)計學意義(P < 0.05)。治療組患者治療后Karnofsky評分、CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺高于治療前,CD⁸⁺低于治療前,同組比較差異有統(tǒng)計學意義(P < 0.05);治療組患者治療后Karnofsky評分、CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺高于對照組,CD⁸⁺低于對照組,兩組比較差異具有統(tǒng)計學意義(P < 0.05)。治療后治療組患者的白細胞減少、血小板減少、惡心嘔吐、腹瀉、口腔黏膜減少、貧血等毒副反應的發(fā)生率顯著低于對照組,兩組比較差異具有統(tǒng)計學意義(P < 0.05)。結論 胎盤多肽聯(lián)合TACE方案治療晚期原發(fā)性肝癌能提高患者的臨床療效,改善生活質(zhì)量,提高患者的免疫功能和減少化療藥物的毒副反應,值得臨床推廣應用。

Objective To explore the clinical effects of placenta polypeptide combined with TACE option in treatment of advanced primary liver cancer. Methods The patients with advanced primary liver cancer (88 cases) of Liaoning Cancer Hospital from February 2011 to December 2013 were randomly divided into control and treatment groups, and each group had 44 cases. The patients in the control group were accepted TACE option. The patients in the treatment group were iv administered with Placenta Polypeptide Injection (8 mL diluted with 250 mL physiological saline) on the basis of control group on days 1 — 14 of one cycle, once daily. The patients in two groups were treated for four cycles. After treatment, the efficacy was evaluated, and the changes of Karnofsky score, immune function indexes and drug adverse reaction were compared. Results The efficacies in the control and treatment groups were 13.64% and 31.82%, respectively, and there were differences between two groups (P < 0.05). After treatment, Karnofsky score, CD³⁺, CD⁴⁺, and CD⁴⁺/CD⁸⁺ in treatment group were higher than before the treatment, CD⁸⁺ was lower, and the difference was statistically significant in the same group (P < 0.05). Karnofsky score, CD³⁺, CD⁴⁺, and CD⁴⁺/CD⁸⁺ in treatment group were higher than those in the control group, while CD⁸⁺ was lower than that in the control group, with the significant difference between two groups (P < 0.05). The incidences of adverse reaction such as leukopenia, thrombocytopenia, nausea, vomiting, diarrhea, reducing of the oral mucosa, and anemia were significantly lower than those in the control group. Conclusion Placenta polypeptide combined with TACE option can improve the clinical curative effect of advanced primary liver cancer, and can improve the quality of life and immune function, while can reduce the adverse reaction of chemotherapy drugs, which is worth clinical popularization and application.